Navigation Links
Novartis Drug Afinitor® Effective in Patients With Non-Cancerous Kidney Tumors Associated With TSC in Phase III Trial
Date:9/23/2011

ignificant improvement in skin lesions including facial angiofibromas was observed, which can be a key concern for people living with TSC."  

Everolimus targets mTOR, a protein that acts as an important regulator of tumor cell division, blood vessel growth and cell metabolism(8). Tuberous sclerosis complex is caused by defects in the TSC1 and/or TSC2 genes(9). When these genes are defective, mTOR activity is increased, which can cause uncontrolled tumor cell growth and proliferation, blood vessel growth and altered cellular metabolism(2,9). By inhibiting mTOR activity in this signaling pathway, everolimus may reduce cell proliferation and blood vessel growth related to angiomyolipoma associated with TSC(2,8,9).

"The positive findings seen in this trial coupled with the known efficacy of everolimus in patients with SEGA point to the important role of mTOR inhibition with everolimus in treating these manifestations of TSC," said Herve Hoppenot, President, Novartis Oncology. "The outcomes support our further research efforts evaluating everolimus as a treatment option across the various conditions associated with TSC."

Affecting approximately 25,000 to 40,000 people in the US and one to two million people worldwide, TSC is associated with a variety of resulting disorders including skin lesions, seizures, swelling in the brain (hydrocephalus) and developmental delays(3,9).

About EXIST-2 EXIST-2 is a prospective, double-blind, randomized, parallel group, placebo-controlled, international, multicenter Phase III study of everolimus versus placebo for the treatment of patients with angiomyolipoma associated with TSC(1,10). Trial patients (median age=31, range 18-61) were randomized 2:1 to receive either everolimus (n=79) or placebo (n=39) at a daily starting dose of 10 mg. By the cut-off of June 30, 2011, the median treatment duration in the double-blind period was 38.1 weeks (range 2-105 weeks) in the everolimus arm and 3
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Novartis Study Showed ACZ885 Provided Substantial Symptom Relief in 84% of Patients With the Most Serious Form of Childhood Arthritis
2. Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis
3. Novartis Drug Gleevec® Shows Significant Overall Survival Benefit for Patients With GIST After Three Years of Adjuvant Treatment vs. One Year
4. Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis
5. Novartis Data Shows ACZ885 for Severe Gouty Arthritis Provided Better Pain Relief and Reduced Risk of New Attacks by Up to 68% vs. Steroid
6. FDA Approves Novartis Drug Afinitor to Treat Pancreatic Neuroendocrine Tumors
7. Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET
8. Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin
9. US Supreme Court Denies Certiorari and Thereby Leaves in Place Second Circuit Ruling That Novartis Pharmaceuticals Corporation Must Pay its Sales Representatives Overtime Compensation
10. Novartis Gains FDA Approval for Amturnide™, a Triple-Combination Pill to Treat High Blood Pressure in Patients Uncontrolled on Two Medications
11. Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... Therapeutics, Inc. (Nasdaq: OREX ) today announced that ... Healthcare Conference in New York . The ... 11 a.m. Eastern Time. To listen to the live webcast ... Relations section of the Company,s Web site at www.orexigen.com ... the event. About Orexigen® Therapeutics Orexigen Therapeutics, ...
(Date:5/17/2013)... 2013   Shareholder rights attorneys  at Robbins Arroyo ... (NASDAQGS: AVEO) securities has filed a complaint in the ... Massachusetts .  The complaint alleges that Aveo and ... of 1934 (the "Exchange Act") between January 3, 2012 ... (Logo: http://photos.prnewswire.com/prnh/20130103/MM36754LOGO ) Aveo ...
(Date:5/17/2013)... 2013  Sony Biotechnology Inc. ("Sony") today announced the ...  Sony will be exhibiting and taking orders for this ... the San Diego Convention Center ... May 20 - 22.  The SP6800 ... audio-visual technologies into new and novel functionalities for the ...
Breaking Medicine Technology:Aveo Pharmaceuticals, Inc. Sued by Investor 2Aveo Pharmaceuticals, Inc. Sued by Investor 3Sony Biotechnology Inc.'s New Technology for Science Provides Researchers Results in Color 2
... , SCHAUMBURG, Ill. , ... privately held specialty pharmaceutical company, today announced that ... vials containing 30 mg per 10 mL and 90 mg per ... Novartis Pharmaceutical Company,s Aredia®, is a bone resorption ...
... , , ... years after the loss of Christopher Jerry,s two-year-old ... Now, as the head of a non-profit foundation working to ... a renewed sense of purpose promoting an all-new life-saving technology ...
Cached Medicine Technology:Sagent Pharmaceuticals Launches Pamidronate Disodium Injection 2Emily Jerry Foundation Endorses Life-Saving Technology 2Emily Jerry Foundation Endorses Life-Saving Technology 3Emily Jerry Foundation Endorses Life-Saving Technology 4
(Date:5/18/2013)... Orlando, FL (May 18, 2013) The use ... for a colonoscopy, according to new research presented ... process, which begins days in advance of the ... preparation medication to be taken at strict intervals. ... for doctors to see cancer and precancerous polyps ...
(Date:5/18/2013)... (May 18, 2013) A ground-breaking advance in ... according to research presented today at Digestive Disease ... minimal withdrawal time for colonoscopies and exploring safer ... colonoscopy, doctors use a device called a colonoscope ... colorectal cancer allows a doctor to look for ...
(Date:5/18/2013)... The “World Healthcare IT Market: Trends & ... market drivers, restraints, and opportunities in North America, Europe, ... 89 market data tables , ... IT Market" , http://www.marketsandmarkets.com/Market-Reports/healthcare-information-technology-market-136.html , ... The global healthcare IT market is expected to grow ...
(Date:5/18/2013)... Fort Wright, KY (PRWEB) May 18, 2013 ... children with hearing loss should consider the legal protections ... liability claim, when problems arise with their child’s treatment ... said today. , Since 1927, the American Speech-Language-Hearing Association ... about communication disorders and to promote treatment, such as ...
(Date:5/18/2013)... Adolescents, especially young males, who experiment ... “K2” are landing in emergency rooms across America. ... epidemic with a new treatment program for those ... research from the National Institute on Drug Abuse, synthetic ... American teenagers. In 2012, 11 percent of high school ...
Breaking Medicine News(10 mins):Health News:New smartphone application improves colonoscopy preparation 2Health News:New colonoscope provides ground-breaking view of colon 2Health News:New colonoscope provides ground-breaking view of colon 3Health News:New colonoscope provides ground-breaking view of colon 4Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 2Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 3Health News:Schachter, Hendy & Johnson PSC Lawyer Says Cochlear Implant Victims Should Know Their Legal Rights 2Health News:Schachter, Hendy & Johnson PSC Lawyer Says Cochlear Implant Victims Should Know Their Legal Rights 3Health News:Spice Addiction Treatment and Synthetic Marijuana Drug Rehab Announced by Recovery Associates 2
... 5 Fewer secondary schools in the United States are ... soda, according to a survey from the Centers for Disease ... seen in states that have adopted strong school nutrition standards ... programs. , The report, "Availability of Less Nutritious Snack ...
... Advice to Eat More Strawberries to Improve Health , ... published in the October 2009 issue of Nutrition Journal, women ... LDL - after a brief period of daily consumption of ... heels of recent research conducted ...
... BlueShield (Empire) proudly announced today that it will be a sponsor ... be held in New York City from August 26 - September ... and wellness activities around Empire,s 75(th) Anniversary this year. , "The ... and women around the world who are there for us when ...
... of Medicine,s (BUSM) Framingham Heart Study (FHS) has received ... Lung, and Blood Institute. According to FHS ... at BUSM and professor of epidemiology at Boston University ... used to add two statisticians to help identify risk ...
... ... measured? , ... October 5, 2009 -- Morehead, the human capital research firm, will host a webinar titled ... on Tuesday, October 20, 2009 at 1:00 p.m. EST. , , ,Patient safety is a ...
... , ... parents don,t understand importance of growth charts/BMI, Children,s National pediatrician stresses the need for ... ... weight growth charts to explain the seriousness of a child being overweight may not ...
Cached Medicine News:Health News:Fewer U.S. Schools Selling Less Nutritious Food and Beverages 2Health News:Emerging Evidence Shows Strawberries Can Help Lower Cholesterol 2Health News:Emerging Evidence Shows Strawberries Can Help Lower Cholesterol 3Health News:Empire BlueCross BlueShield to Support 2011 World Police & Fire Games in NYC 2Health News:Boston University School of Medicine's Framingham Heart Study receives $1M challenge grant 2Health News:Morehead Presents Webinar on "Measuring the Organization's Patient Safety Culture" 2Health News:Pediatrics: Doctors Must Find Better Ways to Talk To Parents about Childhood Obesity 2Health News:Pediatrics: Doctors Must Find Better Ways to Talk To Parents about Childhood Obesity 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: